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Chronic graft-versus-host disease (cGVHD) is a late 
complication of allogeneic hematopoietic stem cell transplant 
(HSCT), occurring in 18% to 70% of recipients.1-3 The oral 
tissues may be involved in up to 90% of the patients that 
present cGVHD in other organs.4-10 Oral mucosa lesions and 
salivary gland dysfunction are the main manifestations of 
oral cGVHD, but a reduction of the mouth opening due to the 
perioral deposition of collagen may also occur.10
Patients with oral involvement of cGVHD may present 
sensitivity, pain, xerostomia, and dysgeusia,10-12 and the 
severity of the oral manifestations may be associated to the 
severity of the disease.5 The sites of the oral mucosa most 
commonly involved by the lesions are the buccal mucosa and 
the tongue.10,13-15 The diagnosis of the oral lesions is based 
on clinical aspects. However, a biopsy of the oral mucosa 
and/or minor salivary glands may be requested when oral 
and systemic signs and symptoms are not sufficient for the 
diagnosis of cGVHD.5
According to the National Institutes of Health (NIH), the 
oral features of cGVHD may be classified as diagnostic (lichen 
planus-like changes, hyperkeratotic plaques, and reduction in 
mouth opening), distinctive (xerostomia, mucoceles, mucosal 
atrophy, pseudomembranes, and ulcers), and common to 
both acute graft-versus-host disease and cGVHD (gingivitis, 
mucositis, erythema, and pain).16-18 The NIH criteria consider 
certain subjective data, such as xerostomia and reduction of 
mouth opening. However, some patients with reduced salivary 
flow rates and reduced range of mouth opening do not present 
these symptoms.10 Thus, a definition of hyposalivation and the 
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expected loss in the range of mouth opening would be more 
valuable for the clinician.
Oral lesions may persist even after the resolution of cGVHD 
in other organs.2 Topical treatment is required in most cases, 
since oral cGVHD lesions do not completely respond to 
systemic therapies.19 Some publications on case series reported 
good responses of oral lesions to topical treatment with 
cyclosporin,20-21 azathioprine,22-23 budesonide,19 tacrolimus,9 
and psoralen/ultraviolet light (PUVA).4,24 Few clinical trials 
have studied the topical treatment of oral cGVHD lesions 
with dexamethasone, budesonide, and PUVA.24-26 Therefore, 
evidence-based studies on the topical treatment of oral cGVHD 
lesions with other drugs are needed.
Patients with oral cGVHD lesions frequently have secondary 
infections, mainly candidiasis. The higher susceptibility to 
fungal infections is due to factors such as the presence of oral 
mucosa lesions,27 the immunosuppressive therapy,2,4,28 and 
the reduced salivary flow rates.1,8,29-35 
The salivary glands represent an important cGVHD 
target,1,6,8,29-36 and the antimicrobial and buffer properties 
of the saliva are important for oral homeostasis.37 However, 
individuals are able to distinguish xerostomia only when the 
salivary flow rates are very low.38 Salivary gland dysfunction 
may be detected by scintigraphy and histopathology, but 
non-invasive exams such as sialometry and sialochemistry 
may detect quantitative and qualitative alterations, 
respectively.37,39,40
Reduced salivary flow rates may lead to discomfort, 
dysphagia, dysphasia, dysgeusia, halitosis, and consequent 
10 REV BRAS HEMATOL HEMOTER. 2014;36(1):9-11
infections, including dental decay and candidiasis.41,42 The 
early diagnosis of salivary gland dysfunction related to cGVHD 
is important for the management of dry mouth complications. 
Moreover, it will help the clinician with the investigation of the 
cGVHD in other organs. The management of hyposalivation 
has been extensively addressed, but only few clinical studies 
verified the improvement of salivary flow rates in a population 
of cGVHD patients.1,29,39,43
Scleroderma may be observed in cGVHD patients, and is 
characterized by cutaneous sclerosis, but may also involve 
oral tissues. An increased deposition of collagen may occur in 
cGVHD patients and lead to a reduction in the mouth opening, 
limited tongue movement, and dysphagia.44,45 This will make 
oral hygiene procedures difficult and may be another factor 
contributing to infections.
In conclusion, oral features are frequently present in 
cGVHD patients. Health care professionals should be aware 
of early oral manifestations of cGVHD in order to manage the 
complications of these conditions.
In this issue of the Revista Brasileira de Hematologia e 
Hemoterapia Gomes et al. evaluate oral cGVHD manifestations 
in less than one year compared to over one year after 
hematopoietic cell transplantation.46
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